FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3096499511> ?p ?o ?g. }

• W3096499511 endingPage "43" @default.
• W3096499511 startingPage "42" @default.
• W3096499511 abstract "Introduction The molecular basis for the clinical heterogeneity observed in DLBCL was initially elucidated with gene expression profiling, identifying three distinct subgroups with prognostic relevance based on COO namely activated B-cell like (ABC), germinal center B-cell like (GCB) and a type 3 subtype. Shortly afterwards the Han's algorithm was developed allowing for widespread applicability and correlation of gene expression with protein expression. GCB profile at diagnosis is generally associated with superior long term outcomes compared to non-GCB in patients treated with conventional chemo-immunotherapy. Patients with relapsed/refractory disease (R/R) after front-line therapy undergo salvage treatment and, upon demonstration of objective response, proceed with high dose therapy and autologous transplantation (auto-HCT). Whether COO by Han's algorithm retains its prognostic significance post auto-HCT in patients with R/R DLBCL is not well established. Methods A retrospective analysis was carried out using the Mayo database across all three sites. It included all patients between 18-75 years of age who were diagnosed with de-novo DLBCL and underwent first auto-HCT for R/R disease. Patients must have received salvage treatment and shown chemotherapy sensitive disease. Patients with transformed DLBCL or other variants and those who underwent auto-HCT in first complete remission for high risk disease were excluded. Patients who had less than a partial response at time of transplantation and still underwent auto-HCT were also excluded. Primary endpoints included overall survival (OS); relapse and relapse-free survival (RFS). Continuous variables were summarized as mean (standard deviation) and median (range). Categorical variables were reported as frequency (percentage). Continuous baseline variables were compared between GCB and non-GCB using Wilcoxon rank sum test and categorical baseline variables were compared with Chi-squared test. Kaplan-Meier method was used to estimate 5 and 10-year rates of freedom from long-term events and draw corresponding survival curves. Multivariate Cox regression models were used to evaluate the impact of cell of origin on long-term survival after adjusting for baseline factors. All tests were two-sided with alpha level set at 0.05 for statistical significance. Results A total of 357 patients underwent auto-HCT between 2005 and 2018. Cell of origin was determined for 284 patients and these were included in the analysis. Median age was 61 (range: 19-78) years, and 64% patients were male. GCB and non-GCB patients did not differ significantly with regards to baseline factors (Table 1). During a median follow up of 1.7 years, 139 patients died, 151 had relapse and 175 either died or had relapse. Five year OS for GCB patients versus (vs) non-GCB was at 44% vs 64% (p=0.004) (Figure 1); relapse was at 67% vs 49% (p=0.012) and RFS was at 28% vs 50% (p=0.003). The difference between GCB and non-GCB groups remained statistically significant in multivariate analysis, with GCB patients 60% more likely to die and 50% more likely to experience relapse compared to non-GCB patients. The only other factor that retained significance in multivariate analysis for both endpoints was response at the time of transplant (Table 2A-C). Conclusions In this analysis, GCB DLBCL results in worse OS and higher relapse vs. non-GCB DLBCL following an auto-HCT. It is unclear if relapse/progression of GCB subtype after front-line therapy alters its natural history into a more aggressive disease. Disclosures Ansell: Trillium: Research Funding; ADC Therapeutics: Research Funding; Affimed: Research Funding; Bristol Myers Squibb: Research Funding; AI Therapeutics: Research Funding; Takeda: Research Funding; Seattle Genetics: Research Funding; Regeneron: Research Funding. Foran:Xencor: Research Funding; Trillium: Research Funding; Takeda: Research Funding; Kura Oncology: Research Funding; Aptose: Research Funding; Aprea: Research Funding; Actinium: Research Funding; Boehringer Ingelheim: Research Funding; Abbvie: Research Funding; BMS: Membership on an entity's Board of Directors or advisory committees; Pfizer: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Revolution Medicine: Consultancy; H3Biosciences: Research Funding; Agios: Honoraria, Research Funding. Tun:Celgene: Research Funding; Mundipharma: Research Funding; Curis: Research Funding; TG Therapeutics: Research Funding; Acrotech: Research Funding; DTRM Biopharma: Research Funding; Bristol-Myers Squibb: Research Funding. Kharfan-Dabaja:Daiichi Sankyo: Consultancy; Pharmacyclics: Consultancy." @default.
• W3096499511 created "2020-11-09" @default.
• W3096499511 creator A5004386819 @default.
• W3096499511 creator A5008583422 @default.
• W3096499511 creator A5012357806 @default.
• W3096499511 creator A5017327825 @default.
• W3096499511 creator A5023628069 @default.
• W3096499511 creator A5026397451 @default.
• W3096499511 creator A5027394636 @default.
• W3096499511 creator A5035051206 @default.
• W3096499511 creator A5037629427 @default.
• W3096499511 creator A5048644166 @default.
• W3096499511 creator A5051399808 @default.
• W3096499511 creator A5059729547 @default.
• W3096499511 creator A5061845933 @default.
• W3096499511 creator A5064206924 @default.
• W3096499511 creator A5071201232 @default.
• W3096499511 creator A5076892547 @default.
• W3096499511 creator A5077118882 @default.
• W3096499511 creator A5084494815 @default.
• W3096499511 creator A5091287816 @default.
• W3096499511 date "2020-11-05" @default.
• W3096499511 modified "2023-09-29" @default.
• W3096499511 title "Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL)" @default.
• W3096499511 doi "https://doi.org/10.1182/blood-2020-136332" @default.
• W3096499511 hasPublicationYear "2020" @default.
• W3096499511 type Work @default.
• W3096499511 sameAs 3096499511 @default.
• W3096499511 citedByCount "0" @default.
• W3096499511 crossrefType "journal-article" @default.
• W3096499511 hasAuthorship W3096499511A5004386819 @default.
• W3096499511 hasAuthorship W3096499511A5008583422 @default.
• W3096499511 hasAuthorship W3096499511A5012357806 @default.
• W3096499511 hasAuthorship W3096499511A5017327825 @default.
• W3096499511 hasAuthorship W3096499511A5023628069 @default.
• W3096499511 hasAuthorship W3096499511A5026397451 @default.
• W3096499511 hasAuthorship W3096499511A5027394636 @default.
• W3096499511 hasAuthorship W3096499511A5035051206 @default.
• W3096499511 hasAuthorship W3096499511A5037629427 @default.
• W3096499511 hasAuthorship W3096499511A5048644166 @default.
• W3096499511 hasAuthorship W3096499511A5051399808 @default.
• W3096499511 hasAuthorship W3096499511A5059729547 @default.
• W3096499511 hasAuthorship W3096499511A5061845933 @default.
• W3096499511 hasAuthorship W3096499511A5064206924 @default.
• W3096499511 hasAuthorship W3096499511A5071201232 @default.
• W3096499511 hasAuthorship W3096499511A5076892547 @default.
• W3096499511 hasAuthorship W3096499511A5077118882 @default.
• W3096499511 hasAuthorship W3096499511A5084494815 @default.
• W3096499511 hasAuthorship W3096499511A5091287816 @default.
• W3096499511 hasBestOaLocation W30964995111 @default.
• W3096499511 hasConcept C126322002 @default.
• W3096499511 hasConcept C143998085 @default.
• W3096499511 hasConcept C2776694085 @default.
• W3096499511 hasConcept C2777408962 @default.
• W3096499511 hasConcept C2778336483 @default.
• W3096499511 hasConcept C2778559949 @default.
• W3096499511 hasConcept C2778822529 @default.
• W3096499511 hasConcept C2779338263 @default.
• W3096499511 hasConcept C2780775027 @default.
• W3096499511 hasConcept C2911091166 @default.
• W3096499511 hasConcept C71924100 @default.
• W3096499511 hasConceptScore W3096499511C126322002 @default.
• W3096499511 hasConceptScore W3096499511C143998085 @default.
• W3096499511 hasConceptScore W3096499511C2776694085 @default.
• W3096499511 hasConceptScore W3096499511C2777408962 @default.
• W3096499511 hasConceptScore W3096499511C2778336483 @default.
• W3096499511 hasConceptScore W3096499511C2778559949 @default.
• W3096499511 hasConceptScore W3096499511C2778822529 @default.
• W3096499511 hasConceptScore W3096499511C2779338263 @default.
• W3096499511 hasConceptScore W3096499511C2780775027 @default.
• W3096499511 hasConceptScore W3096499511C2911091166 @default.
• W3096499511 hasConceptScore W3096499511C71924100 @default.
• W3096499511 hasIssue "Supplement 1" @default.
• W3096499511 hasLocation W30964995111 @default.
• W3096499511 hasOpenAccess W3096499511 @default.
• W3096499511 hasPrimaryLocation W30964995111 @default.
• W3096499511 hasRelatedWork W1963716721 @default.
• W3096499511 hasRelatedWork W2028351944 @default.
• W3096499511 hasRelatedWork W2047078718 @default.
• W3096499511 hasRelatedWork W2088035700 @default.
• W3096499511 hasRelatedWork W2162734426 @default.
• W3096499511 hasRelatedWork W2588676638 @default.
• W3096499511 hasRelatedWork W3193420635 @default.
• W3096499511 hasRelatedWork W4236202711 @default.
• W3096499511 hasRelatedWork W4236395727 @default.
• W3096499511 hasRelatedWork W2254708876 @default.
• W3096499511 hasVolume "136" @default.
• W3096499511 isParatext "false" @default.
• W3096499511 isRetracted "false" @default.
• W3096499511 magId "3096499511" @default.
• W3096499511 workType "article" @default.